Results 141 to 150 of about 71,128 (257)
Conduction of Pragmatic Clinical Trials in Routine Clinical Settings: Guidelines for Development of Protocol. [PDF]
Besekar S, Jogdand S, Patel SS.
europepmc +1 more source
Career development in pragmatic clinical trials to improve care for people living with dementia. [PDF]
Gabbard J +11 more
europepmc +1 more source
ABSTRACT Autism Spectrum Disorder is a neurodevelopmental condition characterized by persistent difficulties in social interaction and communication alongside restricted, repetitive patterns of behavior, interests, or activities. Emerging evidence suggests that bi/multilingualism may enhance social interaction skills, yet prior research has largely ...
Margreet Vogelzang +2 more
wiley +1 more source
Protecting seriously ill populations during pragmatic clinical trials. [PDF]
Teno JM, Hanson LC, Lima JC, Saliba D.
europepmc +1 more source
Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul +7 more
wiley +1 more source
Patient notification about pragmatic clinical trials conducted with a waiver of consent: A qualitative study. [PDF]
Morain SR +3 more
europepmc +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval +6 more
wiley +1 more source
Distinguishing Clinical and Research Risks in Pragmatic Clinical Trials: The Need for Further Stakeholder Engagement. [PDF]
Wilfond BS +6 more
europepmc +1 more source
Aim A prior non‐randomized study suggests that potassium supplementation may improve survival among furosemide initiators, and a randomized trial suggests that salt substitutes containing potassium might lower stroke risk. We conducted a retrospective cohort study using health‐care data to confirm or refute these associations among new users of ...
Thanh Phuong Pham Nguyen +8 more
wiley +1 more source

